Adenocarcinoma of Lung: all 315 studies

Page 2 of 4. Open to participants first (83), then studies with results posted, then the rest; newest registration first within each.

• Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based ChemotherapyCompletedNCT02303977Phase 2Results posted
• A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results posted
• Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedNCT02264210Phase 2Results posted
• Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung CancerCompletedNCT02186847Phase 2Results posted
• Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibCompletedNCT02155465Phase 1/2Results posted
• S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibTerminatedNCT02134912Phase 2Results posted
• Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersCompletedNCT01935336Phase 2Results posted
• Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the LungCompletedNCT01877083Phase 2Results posted
• Sunitinib in Never-Smokers With Lung AdenocarcinomaCompletedNCT01829217Phase 2Results posted
• A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLCTerminatedNCT01798485Phase 3Results posted
• Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung CancerCompletedNCT01737502Phase 1/2Results posted
• A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsCompletedNCT01609543Phase 4Results posted
• Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.TerminatedNCT01578551Phase 2Results posted
• Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung AdenocarcinomaCompletedNCT01565538Phase 2Results posted
• Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT01557959Phase 2Results posted
• LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the LungCompletedNCT01466660Phase 2Results posted
• Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT01386385Phase 1/2Results posted
• SS1P and Pentostatin Plus Cyclophosphamide for MesotheliomaCompletedNCT01362790Phase 1/2Results posted
• MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyCompletedNCT01294306Phase 2Results posted
• Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerCompletedNCT01259089Phase 1/2Results posted
• A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the LungCompletedNCT01218516Phase 2Results posted
• A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]CompletedNCT01003899Phase 2Results posted
• Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00970684Phase 2Results posted
• Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT00955305Phase 2Results posted
• Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung CancerCompletedNCT00950365Phase 2Results posted
• S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung CancerTerminatedNCT00946712Phase 3Results posted
• Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The LungCompletedNCT00818441Phase 2Results posted
• Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to ErlotinibCompletedNCT00716456Phase 1/2Results posted
• S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00368992Phase 2Results posted
• Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic ChemotherapyCompletedNCT00365547Phase 2Results posted
• Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT00334815Phase 2Results posted
• Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung AdenocarcinomaCompletedNCT00284141Phase 2Results posted
• Erlotinib in Women With Previously Untreated Adenocarcinoma of the LungCompletedNCT00137839Phase 2Results posted
• Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung CancerCompletedNCT00126581Phase 2Results posted
• Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerCompletedNCT00118144Phase 2Results posted
• Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by SurgeryCompletedNCT00049543Phase 3Results posted
• Chaigui Jieyu Qufa Decoction for CRF in Driver Gene-negative Lung Adenocarcinoma TrialCompletedNCT07890051Not applicable
• Comparison Paravertebral and Serratus Anterior Plane Block in Video-assisted Thoracoscopic Surgery.Active, not recruitingNCT07002788Not applicable
• Sleep State in Lung Cancer: A Retrospective AnalysisCompletedNCT06953492
• Bioimpedance Analysis in Perioperative Assessment in Thoracic SurgeryActive, not recruitingNCT06796816Not applicable
• Deep Learning Model to Predict the Recurrence of Stage IA Invasive Lung Adenocarcinoma After Sub-lobar ResectionCompletedNCT06659601
• DNA Methylation Biomarkers to Predict Survival After Surgery for Lung AdenocarcinomaCompletedNCT06477211
• NM32-2668 in Adult Patients With Selected Advanced Solid TumorsTerminatedNCT06299163Phase 1
• Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung AdenocarcinomaStatus unknownNCT06104709
• Combined Segmentectomy Versus Lobectomy for Stage IA Lung Adenocarcinoma With Ground-glass Component of Prospective, Randomized, Controlled Clinical StudyActive, not recruitingNCT05983835Not applicable
• Tumor MicroenvironmentActive, not recruitingNCT05982574
• Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsActive, not recruitingNCT05887492Phase 1/2
• Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014)CompletedNCT05794698
• A Study of Tumor-Treating Fields (TTFields) in People With Lung AdenocarcinomaActive, not recruitingNCT05764954Phase 1
• Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung AdenocarcinomaStatus unknownNCT05736991
• Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaStatus unknownNCT05675033Phase 2
• CISH Inactivated TILs in the Treatment of NSCLCWithdrawnNCT05566223Phase 1/2
• Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung AdenocarcinomaStatus unknownNCT05400304
• Exhaled Breath Particles in Lung CancerStatus unknownNCT05395611
• A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionTerminatedNCT05325866Phase 1/2
• Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRsCompletedNCT05292859
• The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.Status unknownNCT05279521Not applicable
• Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)CompletedNCT05252676
• Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung BiopsyCompletedNCT05245630
• Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the LungStatus unknownNCT05228795
• Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse EffectCompletedNCT05204758Phase 3
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05198830Phase 2
• Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung AdenocarcinomaStatus unknownNCT05185544
• Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid ModelStatus unknownNCT05136014
• ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung AdenocarcinomasStatus unknownNCT05079022Phase 1/2
• Identify Prognostic Biomarkers of Lung CancerStatus unknownNCT05010330
• SCION: SABR and Checkpoint Inhibition of NSCLCWithdrawnNCT04944173Phase 2
• Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeActive, not recruitingNCT04929041Phase 2/3
• Radiomics-based Prediction Model of Tumor Spread Through Air Space in Lung AdenocarcinomaCompletedNCT04893200
• Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerWithdrawnNCT04870034Early Phase 1
• IBI188 Combination Therapy in Solid TumorsTerminatedNCT04861948Phase 1
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Advanced Lung Tumor Treated by Osimertinib Plus AnlotinibCompletedNCT04770688Phase 1/2
• The Impact of Polynuclear Neutrophils' Intra-tumoral Rate and the Mutational Status in Pulmonary Adenocarcinomas on SurvivalStatus unknownNCT04761640
• Managed Access Programs for INC280, CapmatinibNo longer availableNCT04741789
• Cios Mobile 3D Spin for Robotic BronchoscopyCompletedNCT04740047
• Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched AnalysisStatus unknownNCT04692935
• A Study of PY314 in Subjects With Advanced Solid TumorsTerminatedNCT04691375Phase 1
• A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT04682431Phase 1
• Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT04625647Phase 2
• 18F-FDG and 68Ga-FAPI PET/CT in Lung AdenocarcinomaCompletedNCT04588064Not applicable
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC PatientsCompletedNCT04566432
• Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary NodulesStatus unknownNCT04554875
• Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital CenterCompletedNCT04493827
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
• TCM in the Treatment of Lung AdenocarcinomaStatus unknownNCT04482829Not applicable
• Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT04459078Phase 2
• A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung CancerTerminatedNCT04432207Phase 1
• Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion VariantsCompletedNCT04370860
• Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung AdenocarcinomaCompletedNCT04310943Phase 2
• Prognostic Role of Positron Emission Tomography and Computed Tomography Parameters in Stage I Lung AdenocarcinomaCompletedNCT04202614
• Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaCompletedNCT04201756Phase 2
• HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)CompletedNCT04165759
• Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter StudyStatus unknownNCT04122833
• The Detection of EGFR Mutations in Liquid Based Cytology SamplesCompletedNCT04086680
• Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma HistologyCompletedNCT04046614Phase 1/2
• Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METActive, not recruitingNCT03993873Phase 1
• CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor HistologyStatus unknownNCT03940846
• Lung Nodule Prospective DatabaseCompletedNCT03922828
• Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver GeneStatus unknownNCT03905317Phase 2

← Adenocarcinoma of Lung overview